Georgieva Julia V, Katt Moriah, Ye Zhou, Umlauf Benjamin J, Wenthur Cody J, Shusta Eric V
Department of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, WI 53706, USA.
Divisions of Pharmaceutical Sciences and Pharmacy Practice, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA.
Pharmaceutics. 2022 Aug 16;14(8):1706. doi: 10.3390/pharmaceutics14081706.
Central nervous system (CNS) exposure to blood-borne biotherapeutics is limited by the restrictive nature of the brain vasculature. In particular, tightly sealed endothelial cells of the blood-brain barrier (BBB) prevent the uptake of protein and gene medicines. An approach to increase the bioavailability of such therapeutics is harnessing the BBB endothelial cells' own receptor-mediated transcytosis (RMT) mechanisms. Key to this process is a targeting ligand that can engage a BBB-resident RMT receptor. We recently identified an antibody, named 46.1, that accumulates in the mouse brain after intravenous injection. To further characterize the brain targeting and penetrating properties of clone 46.1, we conjugated neurotensin (NT) to an scFv-Fc form of the antibody (46.1-scFv-Fc-onginker-NT). While centrally administered NT decreases the core body temperature and locomotor activity, effects attributed to two spatially segregated brain areas, systemically administered NT has limited effects. Hence, NT can be used as a model therapeutic payload to evaluate the brain penetration of BBB-targeting antibodies and their capability to accumulate in discrete brain areas. We demonstrate that intravenously administered 46.1-scFv-Fc-LL-NT can elicit transient hypothermia and reduce drug-induced hyperlocomotion, confirming that 46.1 can deliver drug cargo to the CNS at pharmacologically relevant doses. Interestingly, when two intravenous administration routes in mice, retro-orbital and tail vein, were compared, only retro-orbital administration led to transient hypothermia. We further explored the retro-orbital route and demonstrated that the 46.1-scFv-Fc-LL-NT could enter the brain arterial blood supply directly from the retro-orbital/cavernous sinus. Taken together, the 46.1 antibody is capable of transporting drug cargo into the CNS, and at least of a portion of its CNS accumulation occurs via the cavernous sinus-arterial route.
中枢神经系统(CNS)对血源生物治疗药物的暴露受到脑血管系统限制性的限制。特别是,血脑屏障(BBB)紧密密封的内皮细胞可防止蛋白质和基因药物的摄取。提高此类治疗药物生物利用度的一种方法是利用BBB内皮细胞自身的受体介导转胞吞作用(RMT)机制。这一过程的关键是一种能够与驻留在BBB的RMT受体结合的靶向配体。我们最近鉴定出一种名为46.1的抗体,静脉注射后可在小鼠脑中蓄积。为了进一步表征克隆46.1的脑靶向和穿透特性,我们将神经降压素(NT)与该抗体的单链抗体片段-人Fc段形式(46.1-scFv-Fc-onginker-NT)偶联。虽然中枢给予NT可降低核心体温和运动活性,这些作用归因于两个空间上分离的脑区,但全身给予NT的作用有限。因此,NT可作为一种模型治疗载荷,用于评估靶向BBB的抗体的脑穿透能力及其在离散脑区蓄积的能力。我们证明,静脉注射46.1-scFv-Fc-LL-NT可引起短暂性体温过低并减少药物诱导的运动亢进,证实46.1能够以药理学相关剂量将药物载荷递送至CNS。有趣的是,当比较小鼠的两种静脉给药途径,即眶后注射和尾静脉注射时,只有眶后注射导致短暂性体温过低。我们进一步探索了眶后途径,并证明46.1-scFv-Fc-LL-NT可直接从眶后/海绵窦进入脑动脉血供。综上所述,46.1抗体能够将药物载荷转运至CNS,并且其在CNS中的蓄积至少有一部分是通过海绵窦-动脉途径发生的。